{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-23-000042","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.268128+00:00","generated_at":"2026-06-10T22:47:17.877831+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Nurix signs $60M upfront, $3.4B milestone deal with Seagen for DAC cancer drugs","bullets":["Nurix will use DELigase platform to develop protein degraders for conjugation to antibodies by Seagen.","Upfront cash payment of $60M; eligibility for up to $3.4B in research, development, regulatory and commercial milestones.","Tiered royalties: mid-single to low double digits on future sales; Nurix retains option for U.S. profit sharing and co-promotion on two products.","Seagen responsible for conjugation, preclinical/clinical development and commercialization of Degrader-Antibody Conjugates (DACs)."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-23-000042","json":"https://secwatch.observer/filing/0001549595-23-000042.json","markdown":"https://secwatch.observer/filing/0001549595-23-000042.md","text":"https://secwatch.observer/filing/0001549595-23-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/0001549595-23-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/nrix-20230906.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:47:17.877831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17a382f9e1ae6a1e949d551bb7ecd16f11ac0b68","claim":"Nurix Therapeutics, Inc. entered into Collaboration Agreement with Seagen Inc. valued at $60 million (effective 2023-09-06).","evidence_excerpt":"On September 6, 2023, Nurix Therapeutics, Inc. (“Nurix” or the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Seagen Inc. (“Seagen”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/0001549595-23-000042-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Seagen Inc."},{"label":"Value","value":"$60 million"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}